This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Simon Fraser University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Evaluating the Incorporation of Picolinamide Pendants into the Macropa Scaffold for Pb(II)- and Bi(III)-Based Radiopharmaceuticals.
Inorganic chemistry · 2026
Synthesis and evaluation of HOPO-O8-Methyl-tetrazine as a bifunctional chelator for use in [89Zr]Zr4+, [161Tb]Tb3+ and [227Th]Th4+ radioimmunoconjugates.
Journal of inorganic biochemistry · 2026
Carboxylic- and Amide Donor-Functionalized Pyridine-N-trans-Substituted Cyclen-Based Chelators for 203Pb/212Pb Theranostic Radiopharmaceuticals.
Inorganic chemistry · 2025
Latest funding
- $596,701
Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives
CIHR · 2022 · Nominated PI
- $562,275
Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)
CIHR · 2021 · Co-investigator
26 publications.
Evaluating the Incorporation of Picolinamide Pendants into the Macropa Scaffold for Pb(II)- and Bi(III)-Based Radiopharmaceuticals.
Harriswangler C, Randhawa P, Sommariva-Ucha N, Wharton L, Valencia L, McNeil BL, Yang H, Esteban-Gómez D, Platas-Iglesias C, Ramogida CF
Synthesis and evaluation of HOPO-O8-Methyl-tetrazine as a bifunctional chelator for use in [89Zr]Zr4+, [161Tb]Tb3+ and [227Th]Th4+ radioimmunoconjugates.
Carbo-Bague I, Randhawa P, Tosato M, McNeil BL, Čolović M, London L, Rodríguez-Rodríguez C, Osooly M, Wharton L, Merkens H, Van De Voorde M, Ooms M, Yang H, Bénard F, Ramogida CF
Carboxylic- and Amide Donor-Functionalized Pyridine-N-trans-Substituted Cyclen-Based Chelators for 203Pb/212Pb Theranostic Radiopharmaceuticals.
Mastroianni S, Karpiuk TE, Tosato M, Randhawa P, McNeil BL, Wharton L, McNeil SW, Yang H, Ramogida CF
Chelating [227Th]Th4+ for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
Wharton L, McNeil SW, Meeres H, Zhang D, Ingham A, Merkens H, Osooly M, Rodríguez-Rodríguez C, Bénard F, Yang H
Novel direct alpha spectroscopy technique for225Ac radiopharmaceutical detection in cancer cells.
Farasat M, Saeedi Saghez B, Wharton L, Shapiro S, Vinnick C, Daignault M, Kostashuk M, Pranjatno N, Weiman M, Andreoiu C, Yang H, Kunz P
First preclinical SPECT/CT imaging and biodistribution of [165Er]ErCl3 and [165Er]Er-PSMA-617.
Saeedi Saghez B, Rodríguez-Rodríguez C, Esquinas PL, Merkens H, Bénard F, Radchenko V, Yang H
The H2Sxmacropa Series: Increasing the Chemical Softness of H2macropa with Sulfur Atoms to Chelate Radiometals [213Bi]Bi3+ and [203Pb]Pb2+ for Radiopharmaceutical Applications.
Randhawa P, Kadassery KJ, McNeil BL, MacMillan SN, Wharton L, Yang H, Wilson JJ, Ramogida CF
Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.
Koniar H, Wharton L, Ingham A, Morales Oliver AP, Merkens H, Rodríguez-Rodríguez C, Kunz P, Radchenko V, Yang H, Rahmim A, Uribe C, Schaffer P
Preclinical evaluation of [225Ac]Ac-crown-TATE - An alpha-emitting radiopharmaceutical for neuroendocrine tumors.
Ingham A, Wharton L, Koniar H, Merkens H, McNeil S, Sekar S, Osooly M, Rodríguez-Rodríguez C, Bénard F, Schaffer P, Yang H
Quantitative SPECT imaging of 155Tb and 161Tb for preclinical theranostic radiopharmaceutical development.
Koniar H, McNeil S, Wharton L, Ingham A, Van de Voorde M, Ooms M, Sekar S, Rodríguez-Rodríguez C, Kunz P, Radchenko V, Rahmim A, Uribe C, Yang H, Schaffer P
Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives
Principal investigators: Yang, Hua; Benard, Francois
Keywords: A-Melanocyte-Stimulating Hormone; Alpha Particle Emitting Radionuclides; Melanocortin 1 Receptor; Melenoma Treatment; Radiochemistry Development; Radiopharmaceutical Development; Targeted Radionuclide Therapy
Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)
Principal investigators: Radchenko, Valery; Reilly, Raymond M
Keywords: Radiopharmaceutical Science
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Arman Rahmim and Carlos Uribe: 40 shared papers
- Paul Schaffer and Valery Radchenko: 28 shared papers
- Valery Radchenko and Hua Yang: 17 shared papers
- Kuo-Shyan Lin and Paul Schaffer: 14 shared papers
- Paul Schaffer and Hua Yang: 13 shared papers
- Kuo-Shyan Lin and Valery Radchenko: 7 shared papers
- Kuo-Shyan Lin and Carlos Uribe: 5 shared papers
- Paul Schaffer and Arman Rahmim: 5 shared papers
- Paul Schaffer and Carlos Uribe: 5 shared papers
- Arman Rahmim and Valery Radchenko: 4 shared papers
- Arman Rahmim and Hua Yang: 4 shared papers
- Hua Yang and Carlos Uribe: 4 shared papers
- Kuo-Shyan Lin and Hua Yang: 3 shared papers
- Chemistry
- Molecular Oncology
- Other
Co-authors at Simon Fraser University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.